Abstract
Objective To investigate the changes of T-bet mRNA and GATA-3 mRNA during house dust mite specific immunotherapy (SIT) in peripheral blood mononuclear cells (PBMCs) of allergic asthma patients, and to analyze the mechanism of the treatment. Methods Eighty-nine patients with allergic asthma treated in our hospital from January to December in 2015 were analyzed retrospectively.According to the therapy and prognosis, they were divided into four groups.Twenty-two patients who were treated with SIT and achieved good prognosis were included into the observation group A, 12 patients who were treated with SIT and did not achieve good prognosis were included into the observation group B, 15 patients who were not treated with SIT but achieved good prognosis were included into the control group A, 40 patients who were not treated with SIT and did not achieve good prognosis were included into the control group B. The expressions of T-bet mRNA and GATA-3 mRNA in PBMCs, and the ratio of Th1 and Th2 in peripheral blood of 4 groups before and after treatment were detected and compared. Results In the observation group A and the control group A, expressions of GATA-3 mRNA and ratio of Th2 decreased significantly, T-bet mRNA/GATA-3 mRNA and Th1/Th2 increased significantly.In the observation group A, expressions of T-bet mRNA and ratio of Th1 increased significantly.In the observation group B, expressions of T-bet mRNA and GATA-3 mRNA, ratio of Th1 and Th2 increased significantly.Differences above all were statistically significant (P<0.05). T-bet mRNA/GATA-3 mRNA were positively correlated with Th1/Th2 (Before treatment, r=0.811, P=0.004.After treatment, r=0.801, P=0.000). Conclusions It is helpful to inhibit the excessive expression of GATA-3 mRNA in patients with asthma by using conventional therapy, and the use of SIT can promote the expression of T-bet mRNA at the same time, thus to improve the clinical efficacy. Key words: Allergic asthma; House dust mite specific immunotherapy; T-bet; GATA-3
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
